|
|
|
|
|
|
|
|
|
|
Super Quote | Detail Quote | Interactive Chart | Transaction | Related News | Related Securities | Company Information | Dividend Records | Short Sell
09939 KINTOR PHARMA-B
Nominal 
2.640 +0.020 (+0.763%) | 2025/12 - Final RMB(K¥) | %Chg (Compare to Final) | 2024/12 RMB(K¥) | 2023/12 RMB(K¥) | 2022/12 RMB(K¥) | 2021/12 RMB(K¥) | |
| Turnover | -- | -- | 5,000 | 0 | 0 | 34,231 |
| Cost of Sales | -- | -- | (9,730) | (42,229) | -- | -- |
| Gross Profit | -- | -- | (4,730) | (42,229) | -- | -- |
| 2025/12 - Final RMB(K¥) | %Chg (Compare to Final) | 2024/12 RMB(K¥) | 2023/12 RMB(K¥) | 2022/12 RMB(K¥) | 2021/12 RMB(K¥) | ||
| Change in FV & Impairment on Inv. Prop. | -- | -- | -- | -- | -- | -- | |
| Change in FV & Impairment on Others | -- | -- | (1,206) | -- | -- | -- | |
| Profit / (Loss) on Disposal | -- | -- | -- | -- | -- | -- | |
| Other Non-operating Items | -- | -- | -- | -- | -- | -- | |
| Share of Results of Asso. & JCEs | -- | -- | (1,429) | 52 | (568) | 0 | |
| Profit / (Loss) before Taxation | -- | -- | (155,274) | (1,068,861) | (953,284) | (842,095) | |
| Taxation | -- | -- | (18) | 8,041 | (1,085) | 0 | |
| Profit / (Loss) from Discontinued Operations | -- | -- | -- | -- | -- | -- | |
| Non-controlling Interests | -- | -- | 0 | 0 | 0 | 0 | |
| Others | -- | -- | -- | -- | -- | -- | |
| Profit / (Loss) Attributable to Shareholders | (200,107) | 28.859% | (155,292) | (1,060,820) | (954,369) | (842,095) | |
| 2025/12 - Final RMB(K¥) | %Chg (Compare to Final) | 2024/12 RMB(K¥) | 2023/12 RMB(K¥) | 2022/12 RMB(K¥) | 2021/12 RMB(K¥) | |
| Net Finance Costs / (Income) | -- | -- | 5,068 | (3,387) | 1,305 | (9,555) |
| Depreciation & Amortisation | -- | -- | 17,627 | 18,976 | 18,388 | 10,510 |
| Directors' Emoluments | -- | -- | 10,422 | 27,362 | 18,573 | 6,570 |
| 2025/12 - Final | %Chg (Compare to Final) | 2024/12 | 2023/12 | 2022/12 | 2021/12 | |
| Auditor's Opinion Status | N/A | -- | Unqualified (Modified Report) | Unqualified | Unqualified | Unqualified |
Market Valuation Indicators
| 2025/12 - Final | %Chg (Compare to Final) | 2024/12 | 2023/12 | 2022/12 | 2021/12 | |
| EPS (cts) | -44.000 | 22.222% | -36.000 | -247.000 | -253.000 | -236.000 |
| DPS (cts) | 0.000 | -- | 0.000 | 0.000 | 0.000 | 0.000 |
| Dividend Payout Ratio (%) | -- | -- | -- | -- | -- | -- |
| Cash flow per share ($) | -- | -- | (0.462) | (0.903) | (2.553) | (2.950) |
| NBV per share ($) | -- | -- | 0.657 | 1.024 | 3.341 | 4.270 |
| Remarks: | Real time quote last updated: 02/04/2026 17:59 |
| Real-time basic market prices of Hong Kong securities are provided by HKEx; a Designated Website authorized by the HKEx Group to provide the Service. | |
| Profit / (Loss) Attributable to Shareholders (K¥) | RMB -200,107 |
| %Change | 28.859% |
| EPS / (LPS) | RMB -0.440 |
| NBV Per Share (¥) | RMB -- |